TuHURA Biosciences draws $1.9 million more under Parkview credit line
The company borrowed an additional $1.9 million on June 30, 2026 under its revolving credit facility with Parkview Holdings One LLC, an 8-K filing shows.
TuHURA Biosciences, Inc. disclosed in a Form 8-K dated June 30, 2026 that it took a new draw under its existing loan facility with Parkview Holdings One LLC. The company had previously entered into the Loan Agreement with Parkview Holdings One LLC as lender on April 21, 2026.1 Under that agreement, TuHURA has access to a revolving credit facility with total availability of up to $50 million, running until it matures on April 21, 2031.1
On June 30, 2026, the company drew an additional $1,900,000 from the facility and said it plans to put the money toward general corporate purposes.1 The filing notes that further details on the loan's terms are available in the original agreement, which was attached as an exhibit to TuHURA's 8-K filed on April 22, 2026.
The filing's forward-looking statement section flags risks tied to the arrangement. Among the factors that could affect results, the company cited possible inability to meet drawdown conditions or maintain compliance with the loan terms, the possibility that available funds might not be enough to support its operations and development programs as expected, and potential conflicts of interest since the lender is an affiliate of TuHURA's largest stockholder.1
The report was signed by Dan Dearborn, TuHURA's Chief Financial Officer, and dated July 7, 2026. TuHURA Biosciences trades on The Nasdaq Capital Market under the ticker symbol HURA and is headquartered in Tampa, Florida.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.